Cannabis Bioscience International Holdings (OTCID: CBIH) published a press release on July 20, 2026, unveiling an intranasal nanoemulsion platform for Alzheimer’s research.
Platform targets delivery of selected cannabinoid-based or natural neuroactive compounds, positioning a multi-pathway approach rather than a single-target strategy.
Release cites 7.4 million Americans age 65+ living with Alzheimer’s dementia in 2026, rising to 13.8 million by 2060 without breakthroughs.
Alzheimer’s-related health and long-term care spending estimated at $409 billion in 2026.
CBIH•
